These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 35486581)
1. A database study of clinical and economic burden of invasive meningococcal disease in France. Huang L; Fievez S; Goguillot M; Marié L; Bénard S; Elkaïm A; Tin Tin Htar M PLoS One; 2022; 17(4):e0267786. PubMed ID: 35486581 [TBL] [Abstract][Full Text] [Related]
2. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. Huang L; Heuer OD; Janßen S; Häckl D; Schmedt N PLoS One; 2020; 15(1):e0228020. PubMed ID: 31990941 [TBL] [Abstract][Full Text] [Related]
3. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Wang B; Haji Ali Afzali H; Marshall H Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605 [TBL] [Abstract][Full Text] [Related]
4. The burden of invasive meningococcal disease in the Netherlands, 2011-2020. Middeldorp M; Steens A; Lagerweij G; van Sorge NM; Freudenburg-de Graaf W; A M Sanders E; de Melker HE; Knol MJ Vaccine; 2023 Apr; 41(16):2664-2670. PubMed ID: 36933982 [TBL] [Abstract][Full Text] [Related]
5. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Bénard S; Wright C; Voisine J; Olivier CW; Gaudelus J J Infect Public Health; 2016; 9(3):339-47. PubMed ID: 26688376 [TBL] [Abstract][Full Text] [Related]
6. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Weil-Olivier C; Taha MK; Bouée S; Emery C; Loncle-Provot V; Nachbaur G; Beck E; Pribil C Hum Vaccin Immunother; 2022 Dec; 18(1):2021764. PubMed ID: 35192785 [TBL] [Abstract][Full Text] [Related]
7. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex. Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933 [TBL] [Abstract][Full Text] [Related]
8. Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Weil-Olivier C; Taha MK; Emery C; Bouée S; Beck E; Aris E; Loncle-Provot V; Nachbaur G; Pribil C Infect Dis Ther; 2021 Sep; 10(3):1607-1623. PubMed ID: 34170505 [TBL] [Abstract][Full Text] [Related]
9. Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico. Chacon-Cruz E; Lopatynsky-Reyes EZ; Huerta-Garcia G; Cervantes-Apolinar MY; Guzman-Holst A; Van Oorschot D Hum Vaccin Immunother; 2022 Nov; 18(6):2103319. PubMed ID: 35921223 [TBL] [Abstract][Full Text] [Related]
11. Managing meningococcal disease in the United States: Hospital case characteristics and costs by age. O'Brien JA; Caro JJ; Getsios D Value Health; 2006; 9(4):236-43. PubMed ID: 16903993 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Shen J; Bouée S; Aris E; Emery C; Beck EC Infect Dis Ther; 2022 Feb; 11(1):249-262. PubMed ID: 34791633 [TBL] [Abstract][Full Text] [Related]
13. [Incidence of invasive meningococcal diseases in children in Northern France: usefulness and limits of the discharge code database for correcting compulsory notification data]. Dubos F; Maréchal I; Tilmont B; Courouble C; Leclerc F; Martinot A Arch Pediatr; 2009 Jul; 16(7):984-90. PubMed ID: 19369044 [TBL] [Abstract][Full Text] [Related]
14. Clinical diagnoses and outcomes of 4619 hospitalised cases of laboratory-confirmed invasive meningococcal disease in England: Linkage analysis of multiple national databases. Edge C; Waight P; Ribeiro S; Borrow R; Ramsay M; Ladhani S J Infect; 2016 Nov; 73(5):427-436. PubMed ID: 27475788 [TBL] [Abstract][Full Text] [Related]
15. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Davis KL; Misurski D; Miller J; Karve S Hum Vaccin; 2011 Apr; 7(4):458-65. PubMed ID: 21795848 [TBL] [Abstract][Full Text] [Related]
16. MAGLIO study: epideMiological Analysis on invasive meninGococcaL disease in Italy: fOcus on hospitalization from 2015 to 2019. Tascini C; Iantomasi R; Sbrana F; Carrieri C; D'Angela D; Cocchio S; Polistena B; Spandonaro F; Montuori EA; Baldo V Intern Emerg Med; 2023 Oct; 18(7):1961-1969. PubMed ID: 37528328 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology of invasive meningococcal disease and sequelae in the United Kingdom during the period 2008 to 2017 - a secondary database analysis. Guedes S; Bricout H; Langevin E; Tong S; Bertrand-Gerentes I BMC Public Health; 2022 Mar; 22(1):521. PubMed ID: 35296287 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Sadarangani M; Scheifele DW; Halperin SA; Vaudry W; Le Saux N; Tsang R; Bettinger JA; Clin Infect Dis; 2015 Apr; 60(8):e27-35. PubMed ID: 25605282 [TBL] [Abstract][Full Text] [Related]
19. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Davis KL; Misurski D; Miller JM; Bell TJ; Bapat B Hum Vaccin; 2011 Jan; 7(1):96-101. PubMed ID: 21278486 [TBL] [Abstract][Full Text] [Related]
20. The Health Burden of Invasive Meningococcal Disease: A Systematic Review. Strifler L; Morris SK; Dang V; Tu HA; Minhas RS; Jamieson FB; Deeks SL; Crowcroft NS; Sander B J Pediatric Infect Dis Soc; 2016 Dec; 5(4):417-430. PubMed ID: 26501470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]